| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Seres Therapeutics, Inc. (MCRB) have been net sellers, shedding 490 shares worth roughly $2K on balance.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 12.5K | $24.5K | - | |
| Other | 8.7K | $17.0K | - | |
| Other | 8.6K | $16.8K | - | |
| Other | 8.1K | $15.9K | - | |
| Other | 8.0K | $15.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2016 | David N Cook | Chief Scientific Officer & EVP | Sell | 16,000 | $29.43 | $470,880.00 | -10.0% | |
| May 31, 2016 | John G. Aunins | Chief Technology Officer & EVP | Sell | 14,015 | $30.05 | $421,087.80 | -25.0% | |
| May 25, 2016 | Noubar Afeyan74 | Director, 10% Owner | Sell | 1,000,000 | $27.60 | $27,600,000.00 | -100% | |
| May 24, 2016 | Roger Pomerantz | President and CEO | Sale+OE | 9,801 | $30.00 | $294,030.00 | -5.1% | |
| May 6, 2016 | Roger Pomerantz | President and CEO | Sale+OE | 8,507 | $24.31 | $206,802.52 | -27.2% | |
| May 5, 2016 | Roger Pomerantz | President and CEO | Sale+OE | 59,325 | $26.13 | $1,550,277.92 | -72.3% | |
| May 3, 2016 | Roger Pomerantz | President and CEO | Sale+OE | 67,367 | $28.70 | $1,933,196.89 | -74.8% | |
| Apr 25, 2016 | John G. Aunins | Chief Technology Officer & EVP | Sell | 18,640 | $31.94 | $595,361.60 | -25.0% | |
| Apr 7, 2016 | Roger Pomerantz | President and CEO | Sale+OE | 9,212 | $30.00 | $276,360.00 | -28.8% | |
| Apr 7, 2016 | David N Cook | Chief Scientific Officer & EVP | Sell | 8,000 | $31.00 | $248,000.00 | -4.7% |